| Paul Norman Schultz, MD | |
|
1408 E Barnett Rd, Medford, OR 97504-8279 | |
| (541) 779-2020 | |
| (541) 770-6838 |
| Full Name | Paul Norman Schultz |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 1408 E Barnett Rd, Medford, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265413934 | NPI | - | NPPES |
| 054424 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 18106 (Oregon) | Primary |
| Entity Name | Cataract And Laser Institute Of Southern Oregon Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609913219 PECOS PAC ID: 7517952344 Enrollment ID: O20040420000059 |
News Archive
Scientists from the Institut Pasteur, Paris Descartes University, Sainte-Anne Hospital and the CNRS have recently published a paper in Nature Communications in which they reveal major players in the severe muscle damage caused by sepsis, or septicemia, which explains why many patients suffer debilitating muscle impairment long-term after recovery.
The European Society of Cardiology, through the European Chronic Disease Alliance (ECDA), has urged European heads of state "to show leadership" and long-term commitment to the prevention of chronic non-communicable diseases at today's "high level meeting" of the UN General Assembly in New York.
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).
The use of stem cell therapy to prevent heart attacks is explored in a Comment published in this week's edition of The Lancet.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul Norman Schultz, MD 1408 E Barnett Rd, Medford, OR 97504-8279 Ph: (541) 779-2020 | Paul Norman Schultz, MD 1408 E Barnett Rd, Medford, OR 97504-8279 Ph: (541) 779-2020 |
News Archive
Scientists from the Institut Pasteur, Paris Descartes University, Sainte-Anne Hospital and the CNRS have recently published a paper in Nature Communications in which they reveal major players in the severe muscle damage caused by sepsis, or septicemia, which explains why many patients suffer debilitating muscle impairment long-term after recovery.
The European Society of Cardiology, through the European Chronic Disease Alliance (ECDA), has urged European heads of state "to show leadership" and long-term commitment to the prevention of chronic non-communicable diseases at today's "high level meeting" of the UN General Assembly in New York.
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).
The use of stem cell therapy to prevent heart attacks is explored in a Comment published in this week's edition of The Lancet.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
› Verified 6 days ago
Dr. Justin Matthew Spaulding, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1408 E Barnett Rd, Medford, OR 97504 Phone: 541-779-2020 Fax: 541-770-6838 | |
Yekaterina Joltikov, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1333 E Barnett Rd, Medford, OR 97504 Phone: 541-779-4711 Fax: 541-779-0796 | |
Ms. Allison Rae Jarstad, DO Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1408 E Barnett Rd, Medford, OR 97504 Phone: 541-779-2020 Fax: 541-770-6838 | |
Dr. Craig Augustus Lemley, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1333 E Barnett Rd, Medford, OR 97504 Phone: 541-779-4711 Fax: 541-618-1485 | |
Dr. John Welling, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1333 E Barnett Rd, Medford, OR 97504 Phone: 541-779-4711 Fax: 541-779-0796 | |
Robert Arthur Egan, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 920 Royal Ave, Medford, OR 97504 Phone: 541-732-8400 |